Watson Pharmaceuticals Articles
Lower 4th-qtr 2012 profits at Actavis but beat expectations
19 February 2013
Pfizer prevails in Rapamune patent dispute with Watson
1 February 2013
Watson Pharma now trading as Actavis; Dr Reddy's debuts generic Clarinex Reditabs in USA
28 January 2013
Watson acquires Uteron Pharma; confirms Opana patent challenge
24 January 2013
Patent cliff: one drugmaker's sorrow is another one's joy
20 January 2013
Forest in patent settlement with Glenmark; Watson generic Lysteda cleared; and Dr Reddy's debuts generic Propecia
3 January 2013
US Supreme Court agrees to review pay-for-delay generic deals
10 December 2012
Watson gains FDA approval for generic Revatio
12 November 2012
News briefs: Rituximab biosimilar; Watson to change name; Baxter Brazil plans; India revokes Pegasys patent
5 November 2012
Watson 3rd-qtr EPS jumps 24%, as revenues rise 19%
1 November 2012
Forest Labs links with moksha8 for Viibryd in Latin America; Watson sells minority stake
24 October 2012
Watson gets FDA approval for generic Sanctura XR and Avapro
14 October 2012
Watson sues US FDA regarding generic Actos approval delay
16 August 2012
US FDA approves generics for Actavis and Lupin
6 July 2012
FDA delays approval of QRxPharma's pain drug MoxDuo
29 June 2012
Watson challenges Pfizer's Pristiq patent
26 June 2012
US patent settlements of Xopenex and Lidoderm
30 May 2012
Watson 1st-qtr EPS rise of 84% beats analysts' forecasts
30 April 2012
Watson confirms Abbott Niaspan patent challenge
19 March 2012
Watson 4th-quarter beats expectations, with 93% rise in net income
15 February 2012
Columbia Labs hands over NDA to Watson
13 February 2012
Watson confirms patent challenge to Bayer’s Beyaz
13 February 2012
Watson settles with Janssen over Ortho Tri-Cyclen LO
8 February 2012
Watson settles over Exalgo; gets favorable news on enoxaparin
29 January 2012
Watson buys Strides Arcolab unit for A$375 million; 2011 results
24 January 2012
FDA Advisory thumbs down for Columbia and Watson product
23 January 2012
Mylan confirms Actoplus patent challenge
9 January 2012
Amgen in cancer biosimilars deal with Watson
20 December 2011
Overactive bladder gel gets FDA nod
9 December 2011
Watson and Ranbaxy kick off genericization of Lipitor, launching their approved copies in USA
1 December 2011
Watson posts 23% rise in 3rd-qtr 2011 net revenue; ups forecast
1 November 2011
Watson temporarily restrained from marketing generic Lovenox; challenges Pfizer’s Embeda patent
10 October 2011
Growing scrutiny of pharma facilities exacerbating US drug shortage situation, claims Watson CEO
29 September 2011
Sanofi prevails over Sun Pharma in Eloxatin patent suit; another generic Lovenox approved
20 September 2011
Watson debuts generic Seasonique in USA
28 July 2011
Court rejects Teva's motion to prevent Watson launch of generic Seasonique; nabumetone OKed; Mylan Copaxone judgment
20 June 2011
US FDA approves Actavis generic copy of GSK’s Valtrex and Hi-Tech’s lidocaine; Cephalon wins Fentora patent case
25 March 2011
Elan and Celgene settle over Abraxane; Watson re-challenges Shire Adderall XR patent
28 February 2011
US approval of generic Protonix for Actavis and Risperdal for Taro; Watson does not infringe patent
10 February 2011
As patent cliffs and law suits rule US generic drug industry, research-based majors look to deals and diversification
4 January 2011
US FDA approves Novartis’ Amturnide for BP and Watson’s chewable oral contraceptive, but delays Alimera’s Iluvien
24 December 2010
Takeda settles Actos patent law suits with Mylan, Watson and Ranbaxy, as well as Teva and others
22 December 2010
Watson confirms deal with Natco for generic version of Celgene’s cancer drug Revlimid
8 December 2010
Shire files suit against Impax and Watson over Intuniv patent
6 December 2010
Watson shares jump as firm signs deal with Johnson & Johnson for authorized ADHD drug Concerta generic
3 November 2010
AstraZeneca sees 3rd-qtr 2010 earnings slump 27%, hit by charges and generic competition; sues Watson
28 October 2010
US FDA clears Mylan’s generic versions of Hyzaar and Cozaar and Watson’s copy of Lotrel; Watson settles with Endo
18 October 2010
Watson in partnership with Moksha8 for Brazil and Mexico, inc $30M investment; files for generic Azilect
6 October 2010
Generic drugmakers look set for breakthrough, says new study
22 September 2010
Watson confirms US patent challenge to Allergan’s eye drug Combigan
8 September 2010
Watson and Itero sign worldwide license deal on biologic development candidate for female infertility
16 July 2010
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
